论文部分内容阅读
病例:22例(男14例、女8例),中数年龄65岁(34～81岁),其中18例曾接受过其他方案治疗(2疗程以上者5例),7例曾接受放疗。22例中初治、复发和难治性NHL分别占3例、13例和6例。按国立癌症研究所资助推荐的组织学分类示:滤泡性小裂细胞为主型(F-SCC)6例、弥漫性小裂细胞为主型(D-SCC)1例、滤泡性小裂细胞与大细胞混合型(F-MSCLC)2例、弥漫性小裂细胞与大细胞混合型(D-MSLC)4例、弥漫性大细胞型(D-LC)9例。中度NHL13例,低度NHL9例。方法:环己亚硝脲50mg/m~2口服,第2天足叶乙甙50mg/m~2i.v.第1、8天,氨甲喋呤30mg/m~2 第1、8天,强的松60mg/m~2(最大剂量100mg/d)第1～10天。共治疗6～9疗程,每疗程间隔6周
Cases: 22 cases (male 14 cases, female 8 cases), median age 65 years (34-81 years old), of which 18 cases had received other treatment (5 cases of more than 2 courses), 7 cases had received radiotherapy. Among the 22 cases, the initial, relapsed and refractory NHL accounted for 3, 13 and 6 cases respectively. According to the histological classification recommended by the National Cancer Institute funding, there were 6 cases of follicular small-splitting cells (F-SCC), 1 case of diffuse small fissure cells (D-SCC), and small follicular There were 2 cases of split-cell and large-cell mixed type (F-MSCLC), 4 cases of diffuse small-cell and large-cell mixed type (D-MSLC), and 9 cases of diffuse large cell type (D-LC). There were 13 cases of moderate NHL and 9 cases of low NHL. Method: Cyclohexanil urea 50mg/m~2 orally, on the 2nd day Etoposide 50mg/m~2i.v. On the 1st and 8th days, methotrexate 30mg/m~2 on the 1st and 8th days, prednisone 60mg/m~2 (maximum dose 100mg/d) 1st to 10th days. Total 6 to 9 courses of treatment, 6 weeks apart